Review

Nature Clinical Practice Neurology (2007) 3, 162-172
doi:10.1038/ncpneuro0448  
Received 19 September 2006 | Accepted 19 January 2007

Mechanisms of Disease: DNA repair defects and neurological disease

Kalluri Subba Rao  About the author

Correspondence Indian Council of Medical Research Centre for Research on Aging and Brain, Department of Biochemistry, School of Life Sciences, University of Hyderabad, Hyderabad—500 046 AP, India

Email
 ksrsl@uohyd.ernet.in

Email
 ksrsl@yahoo.com

Summary

In this Review, familial and sporadic neurological disorders reported to have an etiological link with DNA repair defects are discussed, with special emphasis placed on the molecular link between the disease phenotype and the precise DNA repair defect. Of the 15 neurological disorders listed, some of which have symptoms of progeria, six—spinocerebellar ataxia with axonal neuropathy-1, Huntington's disease, Alzheimer's disease, Parkinson's disease, Down syndrome and amyotrophic lateral sclerosis—seem to result from increased oxidative stress, and the inability of the base excision repair pathway to handle the damage to DNA that this induces. Five of the conditions (xeroderma pigmentosum, Cockayne's syndrome, trichothiodystrophy, Down syndrome, and triple-A syndrome) display a defect in the nucleotide excision repair pathway, four (Huntington's disease, various spinocerebellar ataxias, Friedreich's ataxia and myotonic dystrophy types 1 and 2) exhibit an unusual expansion of repeat sequences in DNA, and four (ataxia-telangiectasia, ataxia-telangiectasia-like disorder, Nijmegen breakage syndrome and Alzheimer's disease) exhibit defects in genes involved in repairing double-strand breaks. The current overall picture indicates that oxidative stress is a major causative factor in genomic instability in the brain, and that the nature of the resulting neurological phenotype depends on the pathway through which the instability is normally repaired.

Review criteria

PubMed was searched using Entrez for articles published up to the end of August 2006, including advance online articles. When necessary, related articles made available by PubMed were also searched. Search terms included "DNA repair and neurological diseases", "DNA repair in neurological disorders", "DNA repair pathways in mammalian cells", "DNA repair in brain", and also "DNA repair" in a given disorder such as Alzheimer's disease or Parkinson's disease.

Top

Introduction

Efficient DNA repair mechanisms have evolved to ensure the faithful transfer of the genetic make-up to each new generation. Biological evolution is, however, marked by compelling mutations that escape the watchful DNA repair process. In this cyclic process, the genetic apparatus responsible for DNA damage recognition and repair can itself sustain irreversible mutations that are transmitted to the next generation. This process results in offspring with an inherited defect in DNA repair, which, depending on the genetic characteristics of the transmission, will either be expressed as a disease phenotype or remain dormant. In line with the rising complexity of the higher organisms, both the ways in which genomic DNA can be mutated and the number of pathways through which damage can be repaired have increased enormously through evolution.

For a long time the brain was a neglected organ in terms of studies on DNA transactions. Such neglect was not because the brain was considered unimportant, but—primarily—because the postmitotic nature of adult brain cells results in low levels of DNA synthesis and repair. Over the past two decades, however, our ever-increasing knowledge of neurological disorders and the striking susceptibility of the brain to oxidative DNA damage have resulted in considerable attention being focused on improving our understanding of the brain's DNA repair pathways and genomic stability.

The purpose of this article is to review the current state of knowledge regarding neurological diseases that have been found to be linked to a mutation in a crucial component of a DNA repair pathway. It will focus on the relationship between a given neurological disorder and the type of DNA repair pathway that is compromised, with special emphasis given to oxidative DNA damage and its repair. It will also highlight the fact that some DNA-repair-linked disorders show a mixed phenotype, including neurological symptoms, cancer disposition and accelerated aging, underlining the fundamental importance of the DNA repair machinery in health and disease.

Top

DNA damage in mammalian cells

DNA, being a chemical consisting of base, deoxyribose and phosphate moieties, is vulnerable to attack by other chemicals, which can result in alterations to its coding properties. Damage to the native structure of DNA can occur through two main mechanisms: spontaneous damage caused by sources within a cell's metabolism, and damage caused by external sources such as chemicals and radiation. Protracted oxidative, hydrolytic, deamination or alkylation reactions within a cell can modify DNA bases, or even sometimes cause a complete loss of bases within DNA, resulting in strand breakage. Similarly, cellular DNA can be damaged by external sources such as ultraviolet or ionizing radiations (X-rays, gamma-rays, alpha particles and cosmic rays), and an array of chemical substances can induce interstrand and intrastrand cross-links, DNA–protein cross-links, bulky DNA adducts, and single-strand and double-strand breaks. This subject has been comprehensively reviewed elsewhere.1, 2 In a metabolically active but nondividing cell such as the neuron, about 50,000 DNA-damaging events can be predicted to occur every day. The type of damage occurring in such a cell is likely to be oxidative in nature, and could result in, for example, base modifications, apurinic or apyrimidinic sites, mismatches caused by deamination, or single-strand breaks. The neuronal cellular machinery is endowed with various DNA repair pathways to counteract such damaging events.

Top

DNA repair pathways in mammalian cells

The mammalian DNA repair process has evolved over time into a number of complex pathways to cope with all of the alterations that can occur to the structure of DNA. The past 30 years have seen a great advancement in our understanding of the various DNA repair pathways, both in prokaryotes and in higher organisms. An updated inventory of about 150 human DNA repair genes was recently compiled by Wood et al.,3 and excellent reviews have also appeared in recent times regarding our current knowledge of the DNA repair pathways in eukaryotes,1, 2, 4, 5, 6, 7, 8 of which two have dealt specifically with DNA repair pathways in the brain.1, 8 In mammalian cells there are at least four major pathways: first, a simple reversal of the damage; second, nucleotide excision repair (NER), including mismatch and transcription-coupled repair; third, base excision repair (BER); and last, recombination repair including nonhomologous end joining.

Bacterial photolysis activity is an example of direct reversal of DNA damage. In this repair system an enzyme, with the help of light, monomerizes the pyrimidine dimers in DNA. It is not clear, however, whether a comparable process occurs in humans, so this mode of repair will not be discussed further here.

Excision repair pathways

The excision repair pathway is the predominant, and perhaps universal, mechanism for the maintenance of genomic integrity. This pathway is responsible for repairing a wide variety of DNA lesions, ranging from simple base methylations, to interstrand adduct formation that results in major distortion of the DNA structure. The basic process involved in this pathway consists of four steps: first, recognition and demarcation of the damaged site; second, excision of the damaged portion of DNA and certain adjacent sequences; third, resynthesis of the excised portion using the second strand as a template; and last, ligation of the newly synthesized portion to the existing downstream sequence. As knowledge of the excision repair pathway increased, it became clear that it can be viewed as two distinct streams—NER and BER.

Nucleotide excision repair

NER is a multistep process9 that seems to come into operation to repair such DNA damage as the distinct helical distortion caused by ultraviolet-induced photoproducts. At least 20–30 proteins are involved in the pathway in a sequential manner, and an outline of the pathway is given in Figure 1. The first step involves damage recognition and demarcation, and requires, possibly among many other factors, three proteins—the xeroderma pigmentosum complementing proteins DDB1 (XPE) and XPC, and RD23B–centrin 2. The second step involves the simultaneous arrival of the DNA excision repair proteins ERCC5 (XPG; 3'-endonuclease) and ERCC4 (XPF; 5'-endonuclease complexed with excision repair cross-complementing protein 1), resulting in a dual incision on either side of the damage and removal of an oligonucleotide consisting of around 29 nucleotides. In the third step, the lengthy gap created by removal of the damage-harboring portion is resynthesized using the other strand as a template. In the final step, the newly synthesized portion is ligated to complete the repair process, yielding the repaired DNA product.

Figure 1 An outline of the nucleotide excision repair pathway, which includes global genomic repair (1B) and transcription-coupled repair (1A)
Figure 1 : An outline of the nucleotide excision repair pathway, which includes global genomic repair (1B) and transcription-coupled repair (1A) Unfortunately we are unable to provide accessible alternative text for this. If you require assistance to access this image, or to obtain a text description, please contact npg@nature.com

The damaged base in the DNA is indicated by a green star. In global genomic repair, the damage is recognized by the heterotrimeric complex of XPC, RD23B and centrin 2, whereas when the damage is in a gene that is being actively transcribed by RNA pol II, the Cockayne's syndrome factors ERCC8 and ERCC6 have a crucial role in stalling the transcription process so that repair of the transcribed gene can be initiated. From this point onwards, the repair pathway is common to both mechanisms, and it proceeds by recruiting several other factors, as shown in (2), to effect unwinding, bubble formation of the strand harboring the damage, incision of the strand at discrete points on the 5' and 3' sides, and excision of the fragment containing the damage. The size of the bubble will depend on the nature of damage, which in turn is likely to determine the incision points for the removal of the damaged portion. In step (3), the gap created by the excision of the damaged strand is resynthesized by DNA pol delta/epsilon, with the help of auxiliary factors such as PCNA and RPA–RFC. Finally, DNA ligase I ligates the newly synthesized fragment to the downstream strand to complete the repair process and yield the repaired product (4). Abbreviations: DDB1, xeroderma pigmentosum E; ERCC1, DNA excision repair protein ERCC-1; ERCC2–5, excision repair complementing factors (formerly known as XPD/XPB/XPF/XPG); ERCC6/8, Cockayne's syndrome factor B/A; PCNA, proliferating cell nuclear antigen; pol delta/epsilon, polymerase delta/epsilon; RD23B, RAD23 homolog B (Saccharomyces cerevisiae); RFC, replication factor C; RNA pol II, RNA polymerase II; RPA, replication protein A; XPA, xeroderma pigmentosum A; XPC, xeroderma pigmentosum C.

Full figure and legend (41K)Figures & Tables indexDownload PowerPoint slide (187K)

The mechanism described above can repair damage to any part of the genome. There is, however, an alternative NER pathway that can be used in the early stage of the recognition process to preferentially recognize and repair damage in a genomic area where transcription is occurring simultaneously. This type of NER repair, which is termed transcription-coupled repair, was first described by Bohr et al.,10 and subsequently gained clinical importance.11 It is not yet completely clear how damage in a gene that is being transcribed is preferentially recognized and repaired, although it seems that the factor involved in general recognition of the damage, XPC, is dispensable for transcription-coupled repair.12 Interestingly, Mu and Sancar13 have shown that damage recognition and initiation of repair can be mediated by certain other factors, by blocking RNA polymerase II and dissociating it from the DNA strand to allow repair to proceed first. A role for the Cockayne's syndrome genes ERCC8 (CSA) and ERCC6 (CSB) is envisaged in this function (Figure 1).9

Mismatch repair is responsible for correcting mismatches, such as guanine–thymine nucleotide pairs. Mismatches can result from many factors, including replication errors, spontaneous deamination of bases, oxidation, methylation, and homologous recombination intermediates. Depending on the individual situation, mismatch repair seems to be instigated not only through NER, but also through the other DNA repair pathways such as BER and homologous recombination.14 Indeed, in the brain, the main pathway for mismatch repair is thought to be BER, although many other proteins involved in NER are also found in this organ.8

Base excision repair

BER is perhaps the most fundamental and ubiquitous DNA repair mechanism in all higher organisms that depend on oxygen for the sustenance of life. This pathway has evolved to handle the numerous minor alterations—including spontaneous modification, oxidation, deamination and loss of bases—that can occur in the structure of DNA as a result of cellular metabolic activity. This mode of repair is of particular importance in postmitotic tissues such as those of the brain, where simple base modifications are more likely to occur than is major damage to DNA. An outline of the BER pathway, including the two subpathways known as the short-patch and long-patch repair pathways, is shown in Figure 2. For a more detailed discussion of the BER pathway, the reader is referred to recent reviews.1, 15, 16, 17

Figure 2 Outline of base excision repair showing the two subpathways: (A) the 'short-patch' or single-nucleotide pathway, and (B) the 'long-patch' pathway
Figure 2 : Outline of base excision repair showing the two subpathways: (A) the 'short-patch' or single-nucleotide pathway, and (B) the 'long-patch' pathway Unfortunately we are unable to provide accessible alternative text for this. If you require assistance to access this image, or to obtain a text description, please contact npg@nature.com

Crossing over of the pathways can occur at points (3) and (9). As with nucleotide excision repair, there are essentially four steps in the base excision repair pathway. First, when an altered base is detected (1) the surveillance glycosylases remove that base (2). Next, the endonuclease that is specific for an apurinic or apyrimidinic site cleaves the strand on the 5' side of the abasic site (3). This is followed by filling in of the gap with a correct nucleotide by DNA pol beta, and at the same time releasing the dRP (4). Finally, DNA ligase III ligates the newly introduced nucleotide with the downstream sequence (5), thereby restoring the repaired DNA (6). There are several variations in this process that depend on the nature of the abasic site and the size of the gap to be filled. Sometimes, other DNA polymerases such as DNA polymerase delta or epsilon, along with PCNA, are involved in filling larger sized gaps, also in a strand-displacement manner (long-patch repair [B]; steps 7–12). A more detailed discussion than that supplied in the main text can be obtained from recent review articles1, 15, 16, 17 It has recently been suggested that one of the several newly discovered DNA polymerases, DNA polymerase lambda, has similar properties to that of pol beta and might participate in base excision repair.61 Abbreviations: APE1, human apurinic/apyrimidinic endonuclease 1; DB, damaged base; dNTPs, deoxynucleoside triphosphates; dRP, deoxyribose 5'-phosphate; FEN1, flap structure-specific endonuclease 1; gly, DNA glycosylase; lig I/III, DNA ligase I/III; PARP1, poly (ADP-ribose) polymerase 1; PCNA, proliferating cell nuclear antigen; PNKP, polynucleotide kinase 3'-phosphatase; pol beta/delta/epsilon, DNA polymerase beta/delta/epsilon; WRN, Werner syndrome ATP-dependent helicase; XRCC1, X-ray repair cross-complementing protein 1. Permission obtained from Elsevier B.V. © Rao KS (2006) DNA repair in aging rat neurons. Neuroscience [doi:10.1016/j.neuroscience.2006.09.032].

Full figure and legend (61K)Figures & Tables indexDownload PowerPoint slide (232K)

Recombination repair pathways

Damage to DNA that occurs in the form of a double-strand break, for instance as a result of ionizing radiation or chemicals that induce interstrand and intrastrand cross-links, eliminates the possibility of using one of the strands as a template for the repair process. Such damage is therefore addressed by recombination repair.18, 19 Recombination repair is of two types: homologous recombination and nonhomologous end joining. Homologous recombination is a complex and poorly understood process that involves using an intact homologous DNA strand as a template to repair a double-strand break. Nonhomologous end joining, by contrast, involves religation of the broken ends without any regard to homology, and is consequently relatively error-prone,7 but it is nevertheless a major pathway for double-strand-break repair in mammalian cells and is thought to be of vital importance in postmitotic tissue. Indeed, the existence of this activity in adult as well as aging brain cells has been demonstrated.20, 21 Finally, a new dimension has been added to our understanding of the DNA repair mechanisms in mammalian cells, with the discovery of a number of novel DNA polymerases that have the capacity to carry out DNA synthesis across a damaged or altered base; this process is known as translesion synthesis.22, 23 These polymerases have differing substrate specificities, enabling them to deal with many different types of damaged bases.

Top

Neurological diseases linked to DNA repair defects

Any recent text book of neurology will list at least 200 neurological disorders, with diverse etiologies and genetic characteristics. A number of these disorders have a definitive link to an inherited or acquired defect in one of the DNA repair pathways. Table 1 lists these disorders along with the known genetic DNA repair defect and the nature of the inheritance. In addition, there are a handful of syndromes with an etiological link to DNA damage and repair that exhibit symptoms of accelerated aging but have no striking neurological symptoms. Such syndromes include Werner's syndrome, Bloom syndrome and Rothmund–Thomson syndrome (none of which is included in Table 1).

Table 1 Neurological disorders with a link to defective DNA repair
Table 1 - Neurological disorders with a link to defective DNA repair
Full tableFigures & Tables indexDownload PowerPoint slide (286K)

The syndromes and diseases listed in Table 1 show some variation in the precise pathway or gene involved in the associated defective DNA repair mechanism. The first four disorders seem to result from defects in the excision repair pathway. In view of their overlapping symptoms, they are discussed together here.

Xeroderma pigmentosum, Cockayne's syndrome, trichothiodystrophy and Down syndrome

In the case of xeroderma pigmentosum, seven complementation groups (XPA, ERCC3 [XPB], XPC, ERCC2 [XPD], DDB1, ERCC4 and ERCC5) correspond to mutations in seven genes that have a role in NER (Figure 1). An additional variant, xeroderma pigmentosum V, is caused by a mutation in a novel DNA polymerase eta belonging to the Y family of DNA polymerases, which supports translesion synthesis.24, 25 An interesting disease feature seen in some, but not all, patients with xeroderma pigmentosum is progressive neurodegeneration. Patients who experience severe neurodegeneration are often found to have mutations in components of the transcription-coupled repair system, such as the Cockayne's syndrome proteins ERCC8 (CSA) and ERCC6 (CSB; see below), and common genes such as XPA, ERCC2 (previously XPD), ERCC3 (XPB), ERCC4 (previously XPF) and ERCC5 (previously XPGC).

Cockayne's syndrome is an autosomal recessive disease, symptoms of which include growth retardation, deafness, dysmyelination in white matter, and retinal and Purkinje's cell degeneration. This syndrome is not associated with cancer or loss of personality. The two proteins found to be mutated in this syndrome, ERCC8 and ERCC6, have been shown to be required for transcription-coupled repair.

Some information regarding the precise role of the ERCC6 and ERCC8 protein factors in transcription-coupled repair is now known. The most recent studies, from two independent groups,26, 27 can be summarized as follows. ERCC8 is a subunit of E3 ubiquitin ligase complex, which is part of the ubiquitination machinery, and ERCC6 is the substrate for this ligase. When exposure to ultraviolet light stalls the RNA-polymerase-II-mediated transcription process, ERCC6 fulfills the role of attracting all the factors needed for transcription-coupled repair, which include the ERCC8–DDB1–ubiquitin ligase complex. Once the repair process is completed, ERCC6 is degraded in a proteasome in an ERCC8-dependent manner through ubiquitination. This degradation seems to be the tail-end process of DNA repair that allows transcription to proceed normally. There is also a syndrome closely related to Cockayne's syndrome known as cerebro-oculo-facio-skeletal syndrome, which involves mutations in ERCC2, ERCC5 and ERCC6. Details of this disorder are provided by Graham and co-workers.28 Most of the symptoms of this autosomal recessive disease are similar to those of Cockayne's syndrome, except that cerebro-oculo-facio-skeletal syndrome is also associated with more-severe eye defects such as microcornea.

The main symptoms of cancer disposition in xeroderma pigmentosum are seen when mutations are found in genes that are unique to global genome repair and have no role in transcription-coupled repair; for example, XPC and DDB1 (XPE), and replication polymerase eta. Considerable evidence is accumulating to indicate that lack of efficient NER leads to neurodegeneration. Mutations in three other genes, ERCC2, ERCC3 and ERCC5, can result in combined symptoms of either xeroderma pigmentosum and trichothiodystrophy or xeroderma pigmentosum and Cockayne's syndrome, depending on the type of mutation carried.8, 25 The symptoms of trichothiodystrophy are developmental abnormalities, with sulfur-deficient brittle hair and skin photosensitivity, growth retardation and neurological abnormalities. Recently, Andressoo et al.29 reported a knock-in Ercc2 mouse model for combined xeroderma pigmentosum and Cockayne's syndrome that exhibited both cancer and segmental progeria, and the fibroblasts from these animals showed defective repair of oxidative DNA lesions.

In addition to the classical trisomy of chromosome 21, evidence is emerging that people with Down syndrome have defective DNA repair mechanisms, particularly with respect to NER. In an age-matched and sex-matched controlled study, Raji and Rao30 showed that the activities of enzymes such as polymerase beta, polymerase epsilon and two endo-DNases were adversely affected in the peripheral lymphocytes of patients with Down syndrome compared with normal controls. The capacity for lymphocyte repair also rapidly declined with age in patients with Down syndrome compared with normal subjects. Further evidence has emerged to indicate that there is an inherited defect in DNA repair in Down syndrome, particularly regarding the repair of oxidative damage. For example, unusually high levels of several gene products involved in the repair of oxidative damage, such as Cu–Zn superoxide dismutase (SODC, also known as SOD1),31 XRCC1, ERCC2, ERCC3, transcription factor TAF–DBP and elongation factor EF1A,32 have been found in patients with Down syndrome, indicating cellular oxidative stress. Recently, Zana et al.33 reported finding elevated numbers of DNA single-strand breaks and oxidized bases in the lymphocytes of patients with Down syndrome. Unrepaired oxidative DNA damage in the brain might, therefore, be a causative factor in the mental retardation seen in Down syndrome.

Ataxia-telangiectasia, Nijmegen breakage syndrome and ataxia-like disorder

Ataxia-telangiectasia, Nijmegen breakage syndrome and ataxia-telangiectasia-like disorder are generally considered to be chromosome instability disorders, and the associated defective genes in these diseases are ATM,34NBN—also known as nibrin35—and MRE11,36 respectively. All of these genes are involved in eliciting a response to DNA damage, in particular double-strand breaks that result from ionizing radiation. ATM belongs to the phosphatidylinositol kinase family, is activated by ionizing radiation, and phosphorylates nibrin in the MRN (MRE11–RAD50–nibrin) complex.37 This complex is linked to DNA damage processing, in particular double-strand-break repair through recombination,38 but also telomere-length maintenance.39 It is not clear, however, whether ATM or the MRN complex have any role other than to activate the response to the DNA damage that might be connected to the cerebellar neurodegeneration seen in the above disorders. Lee et al.40 have proposed that ATM might activate the apoptosis signaling pathway to eliminate neurons with a heavy load of DNA damage. Recently, Biton et al.,41 working with human neuron-like cells in culture, observed that the ATM-mediated response to double-strand breaks is similar to that in proliferating cells. Knocking out ATM did not interfere with neuronal differentiation, but it abolished the ATM-mediated response to DNA damage. The damage response cascade, which is perhaps not yet completely understood, therefore seems to be important to effect repair, although the 'apoptosis' hypothesis also looks attractive.

Alzheimer's disease and Parkinson's disease

Of all the diseases listed in Table 1, Alzheimer's disease and Parkinson's disease are probably the two that are gaining the most attention at present. Both of these disorders are devastating in nature, have familial and sporadic forms, and are attributable to a vulnerable genetic lineage combined with aging and possibly as-yet-unknown lifestyle factors. A voluminous literature is available on both of these disorders, particularly in relation to their association with aging. Only those observations that indicate a link with DNA repair defects will be mentioned here.

The hallmark symptom of Alzheimer's disease is cognitive decline; therefore, it was only natural that people would investigate, among other things, genomic damage and its repair in the CNS—whenever possible in affected patients, but also in other tissues or experimental models. In 1987, Robinson and co-workers42 reported that alkylation damage is inefficiently repaired in cells from patients with Alzheimer's disease. They postulated that this could be the cause of late-onset familial Alzheimer's disease and the associated damage to the CNS. Since then, a large body of information has established that there is accumulated oxidative DNA damage in the cells of patients with Alzheimer's disease.43 Many other studies have shown that there is both increased DNA damage and decreased DNA repair in patients with Alzheimer's disease (for a recent review see Fishel et al.44). It is noteworthy that the two DNA repair pathways that are most likely to be adversely affected in Alzheimer's disease are BER44 and nonhomologous end joining.45 So far, however, there has not been any unequivocal identification of a precise locus or gene (or genes) that is affected in these pathways.

Oxidative stress and DNA damage are also implicated in Parkinson's disease. Increased levels of oxidative stress as well as expression of the mitochondrial BER enzyme 8-oxoguanosine DNA glycosylase (OGG1) have been reported to occur in the substantia nigra region of the brain in patients with Parkinson's disease.46 The cell death mechanism in this disorder is, however, proving elusive.

Huntington's disease, spinocerebellar ataxias, Friedreich's ataxia, and myotonic dystrophy types 1 and 2

Huntington's disease, the spinocerebellar ataxias, Friedreich's ataxia and myotonic dystrophy types 1 and 2 are all hereditary disorders in which there is an expansion of repeat sequences in DNA. Several such neurological disorders are known, but only a few representative syndromes are mentioned here. In Huntington's disease and various spinocerebellar ataxias, the defect takes the form of an expanded CAG repeat sequence. In Huntington's disease, the unstable CAG expansion (more than 40 repeats) occurs within a gene located on chromosome 4 that was originally called IT15, but has since been renamed HD or huntingtin. The CAG expansion results in a polyglutamine (poly-Q) track in the N-terminal region of the huntingtin protein, which causes the abnormal degradation of this protein into small fragments that undergo ubiquitination; these fragments move from the cytosol to the nucleus and aggregate to cause damage and induce apoptosis.47, 48 It is not clear, however, why only some neurons in the corpus striatum and cerebral cortex are susceptible. There are two chromosomal loci—one at 6q23–24 and the other at 18q22—that are capable of modifying the age of onset of Huntington's disease.49 Furthermore, it is becoming clear that in this disease transcriptional dysregulation via histone acetylation might be one of the factors causing neuronal dysfunction.50 The same events are likely to take place in all of the other poly-Q disorders, including spinocerebellar ataxias and spinal and bulbar muscular atrophy, although the identity of the gene showing the CAG expansions varies.51 In Friedreich's ataxia, expansion of the trinucleotide GAA occurs in the first intron of the gene on chromosome 9 that codes for frataxin (FRDA) protein, whereas in myotonic dystrophy either the CAG (type 1) or the CCTG (type 2) expansions are seen in a zinc finger protein 9 (CNBP) gene.52

Spinocerebellar ataxia with axonal neuropathy-1 and triple-A syndrome

In spinocerebellar ataxia with axonal neuropathy-1 (SCAN1), there is a progressive degeneration of postmitotic neurons. El-Khamisy and co-workers53 have recently demonstrated that this neurodegenerative disease results from a mutation in the gene encoding tyrosyl DNA phosphodiesterase 1 (TDP1). In lower eukaryotes, TDP1 is known to facilitate double-strand-break repair by removing the topoisomerase I peptide from DNA termini. A mutation in this enzyme produces no distinct phenotype, however, and is therefore unlikely to account for the progressive neuronal degeneration noticed in SCAN1. El-Khamisy and his group53 have, therefore, looked for a different role for TDP1 in human cells. They found that TDP1 is required for the repair of chromosomal single-strand breaks arising from abortive topoisomerase I activity or oxidative stress. This group has also shown that TDP1 is part of the multiprotein single-strand-break repair complex and directly interacts with DNA ligase IIIalpha, and that this complex is inactive in SCAN1 cells. These findings are of considerable importance, as they indicate the existence of a TDP1-dependent single-strand-break repair pathway in differentiated neurons that is deficient in SCAN1 patients. Normally, single-strand breaks or gaps are repaired in neurons through BER, in which both DNA ligase IIIalpha and XRCC1 participate, along with polynucleotide kinase.1 It therefore seems that the TDP1-dependent single-strand-break repair is a slightly different mode of single-strand-break repair, and could be of considerable importance in brain cells where it deals with single-strand breaks resulting from a variety of causes.

Yet another hereditary disease with neurological symptoms and a defect in the repair of DNA single-strand breaks has been recognized.54 This disease is called triple-A (achalasia–addisonian–alacrima) syndrome, and it was found to be caused by a mutation in a gene called AAAS (located on chromosome 12q13), which codes for a protein named ALADIN. Triple-A syndrome shows considerable genetic heterogeneity. ALADIN is a component of the nuclear pore complex, and mutant ALADIN fails to target this complex. The consequences of this failure were recently investigated using fibroblasts from patients with triple-A syndrome.55 Mutant ALADIN was found to decrease the nuclear accumulation of both apratoxin, a repair protein for DNA single-strand breaks, and DNA ligase I; this decrease was reversed by wild-type ALADIN.

Amyotrophic lateral sclerosis

The precise mechanism of motor neuron death in amyotrophic lateral sclerosis (ALS) remains elusive. A mutation in the SOD1 gene is known to be present in the familial form,56 however, which is a definite indicator that oxidative stress could have an important role in the disease. Indeed, cell-permeable antioxidant peptides have been suggested as a potential therapeutic approach.57 The SOD1 mutation might not be the sole cause of ALS, however, as Sod1 knockout mice have been found to survive for long periods without any motor neuron degeneration. The SOD1 mutation might, therefore, mediate other changes that lead to the death of motor neurons.47 Further supporting oxidative stress as a major factor in ALS, Kikuchi et al.58 have shown impaired mitochondrial repair of 8-oxo-guanine in the spinal motor neurons of patients with ALS. Similarly, Nagano et al.59 observed decreased levels of phosphatidylinositol 3 kinase, its downstream effector Akt/protein kinase B, and AP endonuclease in transgenic mice expressing mutant SOD1. It should be noted that these factors are all involved in the normal DNA damage response and in BER. Furthermore, Oh et al.60 reported increased expression of apoptosis-inducing factor (AIF) in the spinal cords of SOD1 Gly93Ala transgenic mice as their ALS disease progressed.

Top

Conclusion and perspectives

All genetically transmitted disorders or syndromes are essentially caused by a mutation that has been sustained because of a lack of DNA repair, which has then been transmitted to the next generation. What happens if the mutation is in that part of the genomic DNA involved in DNA repair? The consequences would be highly deleterious in the offspring. A number of neurological disorders, as discussed in this Review, seem to have an etiological connection to defects in one or more DNA repair pathways. What is interesting is the fact that even repair defects that have no immediate relevance to the brain genome (for example, an inability to repair ultraviolet-induced DNA damage) will eventually cause neurological abnormalities. In those diseases that are primarily neurological in nature (whether familial or sporadic), however, the vulnerability for defective DNA repair can be expected to appear in the CNS. In this regard, the most important culprit for causing DNA damage in the brain seems to be oxidative stress, and the most important DNA repair pathway to deal with such damage in the brain is BER. This is not to say that the mutations responsible for these disorders are always located in the genes involved in BER, but they do seem to constitute a high proportion. The ubiquitous BER, therefore, seems to be emerging as a guardian against the body's internal forces that cause DNA damage in the brain and possibly in the rest of the body, and should as a consequence become a main therapeutic target. This is the rich dividend of information with which research on neurological diseases has provided us.

Key points

  • The native structure of genomic DNA can be damaged in many ways, both by external agents and from within the cell as a consequence of normal metabolism
  • In an effort to maintain their genomic integrity, organisms have evolved a number of pathways to repair DNA damage
  • Mutations in genes coding for proteins involved in DNA repair pathways can lead to abnormal phenotypes, including neurological disorders, cancer and premature aging; many such conditions are found to have an etiological link to defects in one or more DNA repair pathways
  • In a postmitotic organ such as the brain, the base excision repair pathway—a conserved mode of DNA repair that deals with the oxidative damage that can result from internal forces—has an important role, and could be a viable candidate for therapeutic targeting

Acknowledgments

KS Rao would like to acknowledge the help of his colleague Umakanth Swain in drawing the original artwork for figure 1.

References

  1. Rao KS (2003) DNA-repair in brain aging: the importance of base excision repair and DNA polymerase beta. Proc Indian Natl Sci Acad B69: 141–156
  2. Reddy MC and Vasquez KM (2005) Repair of genome destabilizing lesions. Radiat Res 164: 345–356 | Article | PubMed | ChemPort |
  3. Wood RD et al. (2005) Human DNA repair genes, 2005. Mutat Res 577: 275–283 | PubMed | ISI | ChemPort |
  4. Wood RD (1996) DNA repair in eukaryotes. Annu Rev Biochem 65: 135–167 | Article | PubMed | ISI | ChemPort |
  5. Hoeijmakers JHJ (2001) genomic maintenance mechanisms for preventing cancer. Nature 411: 366–374 | Article | PubMed | ISI | ChemPort |
  6. Mellon I (2005) Transcription-coupled repair: a complex affair. Mutat Res 577: 155–161 | PubMed | ISI | ChemPort |
  7. Hefferin ML and Tomkinson AE (2005) Mechanism of DNA double-strand break repair by non-homologous end joining. DNA Repair (Amst) 4: 639–648 | PubMed | ChemPort |
  8. Brooks PJ (2002) DNA repair in neural cells: basic science and clinical implications. Mutat Res 509: 93–108 | PubMed | ChemPort |
  9. de Boer J and Hoeijmakers JH (2000) Nucleotide excision repair and human syndromes. Carcinogenesis 21: 453–460 | Article | PubMed | ISI | ChemPort |
  10. Bohr VA et al. (1985) DNA repair in an active gene: removal of pyrimidine dimers from the DHFR gene of CHO cells is much more efficient than in the genome overall. Cell 40: 359–369 | Article | PubMed | ISI | ChemPort |
  11. Hanawalt PC (1994) Evolution of concepts in DNA repair. Environ Mol Mutagen 23: 78–85 | Article | PubMed |
  12. Venema J et al. (1991) Xeroderma pigmentosum complementation group C cells remove pyrimidine dimmers selectively from the transcribed strand of active genes. Mol Cell Biol 11: 4128–4134 | PubMed | ISI | ChemPort |
  13. Mu D and Sancar A (1997) Model for XPC-independent transcription-coupled repair of pyrimidine dimmers in humans. J Biol Chem 272: 7570–7573 | Article | PubMed | ISI | ChemPort |
  14. Schofield MJ and Hsieh P (2003) DNA mismatch repair: molecular mechanisms and biological function. Annu Rev Microbiol 57: 579–608 | Article | PubMed | ISI | ChemPort |
  15. Barnes DE and Lindahl T (2004) Repair and genetic consequences of endogenous DNA base damage in mammalian cells. Annu Rev Genet 38: 445–476 | Article | PubMed | ISI | ChemPort |
  16. Frosina G et al. (1996) Two pathways for base excision repair in mammalian cells. J Biol Chem 271: 9573–9578 | Article | PubMed | ISI | ChemPort |
  17. Sokhansanj BA and Wilson DM III (2006) Estimation of the effect of human base excision repair protein variants on the repair of oxidative DNA base damage. Cancer Epidemiol Biomarkers Prev 15: 1000–1008 | Article | PubMed | ChemPort |
  18. Dronkert ML and Kanaar R (2001) Repair of DNA interstrand cross-links. Mutat Res 486: 217–247 | Article | PubMed | ISI | ChemPort |
  19. Thompson LH and Schild D (2002) Recombinational repair and human disease. Mutat Res 509: 49–78 | Article | PubMed | ISI | ChemPort |
  20. Ren K and de Ortiz SP (2002) Non-homologous DNA end joining in mature rat brain. J Neurochem 80: 949–959 | Article | PubMed | ChemPort |
  21. Vyjayanti VN and Rao KS (2006) DNA double strand break repair in brain: reduced NHEJ activity in aging rat neurons. Neurosci Lett 393: 18–22 | Article | PubMed | ChemPort |
  22. Rattray AJ and Strathern JN (2003) Error-prone DNA polymerases: when making a mistake is the only way to get ahead. Annu Rev Genet 37: 31–66 | Article | PubMed | ISI | ChemPort |
  23. Lehmann AR (2006) Translesion synthesis in mammalian cells. Exp Cell Res 312: 2673–2676 | Article | PubMed | ChemPort |
  24. Gratchev A et al. (2003) Molecular genetics of xeroderma pigmentosum variant. Exp Dermatol 12: 529–536 | Article | PubMed | ISI | ChemPort |
  25. Cleaver JE (2005) Cancer in xeroderma pigmentosum and related disorders of DNA repair. Nat Rev Cancer 5: 564–573 | Article | PubMed | ISI | ChemPort |
  26. Groisman R et al. (2006) CSA-dependent degradation of CSB by the ubiquitin-proteasome pathway establishes a link between complementation factors of the Cockayne syndrome. Genes Dev 20: 1429–1434 | Article | PubMed | ChemPort |
  27. Fousteri M et al. (2006) Cockayne syndrome A and B proteins differentially regulate recruitment of chromatin remodeling and repair factors to stalled RNA polymerase II in vivo. Mol Cell 23: 471–482 | Article | PubMed | ChemPort |
  28. Graham JM Jr et al. (2001) Cerebro-oculo-facio-skeletal syndrome with a nucleotide excision-repair defect and mutated XPD gene, with prenatal diagnosis in a triplet pregnancy. Am J Hum Genet 69: 291–300 | Article | PubMed | ISI | ChemPort |
  29. Andressoo JO et al. (2006) An Xpd mouse model for the combined xeroderma pigmentosum/Cockayne syndrome exhibiting both cancer predisposition and segmental progeria. Cancer Cell 2: 121–132 | Article |
  30. Raji NS and Rao KS (1998) Trisomy 21 and accelerated aging: DNA-repair parameters in peripheral lymphocytes of Down's syndrome patients. Mech Ageing Dev 100: 85–101 | Article | PubMed | ChemPort |
  31. Druzhyna N et al. (1998) Defective repair of oxidative damage in mitochondria DNA in Down's syndrome. Mutat Res 409: 81–89 | PubMed | ISI | ChemPort |
  32. Fang-Kircher SG et al. (1999) Increases steady state mRNA levels of DNA-repair genes XRCC1, ERCC2 and ERCC3 in brain of patients with Down syndrome. Life Sci 64: 1689–1699 | Article | PubMed | ChemPort |
  33. Zana M et al. (2006) Age-dependent oxidative stress-induced DNA damage in Down's lymphocytes. Biochem Biophys Res Commun 345: 726–733 | Article | PubMed | ChemPort |
  34. Savitsky K et al. (1995) A single ataxia telangiectasia gene with a product similar to PI-3 kinase. Science 268: 1749–1753 | Article | PubMed | ISI | ChemPort |
  35. Carney JP et al. (1998) The hMre11/hRad50 protein complex and Nijmegen breakage syndrome: linkage of double-strand break repair to the cellular DNA damage response. Cell 93: 477–486 | Article | PubMed | ISI | ChemPort |
  36. Stewart GS et al. (1999) The DNA double-strand break repair gene hMRE11 is mutated in individuals with an ataxia-telangiectasia-like disorder. Cell 99: 577–597 | Article | PubMed | ISI | ChemPort |
  37. Gatei M et al. (2000) ATM-dependent phosphorylation of nibrin in response to radiation exposure. Nat Genet 25: 115–119 | Article | PubMed | ISI | ChemPort |
  38. de Jager M et al. (2001) Human Rad50/Mre11 is a flexible complex that can tether DNA ends. Mol Cell 8: 1129–1135 | Article | PubMed | ISI | ChemPort |
  39. D'Amours D and Jackson SP (2002) The Mre 11 complex: at the cross-roads of DNA repair and check signaling. Nat Rev Mol Cell Biol 3: 317–327 | Article | PubMed | ISI | ChemPort |
  40. Lee Y et al. (2001) Ataxia telangiectasia mutated-dependent apoptosis after genotoxic stress in the developing nervous system is determined by cellular differentiation status. J Neurosci 21: 6687–6693 | PubMed | ISI | ChemPort |
  41. Biton S et al. (2006) Nuclear ataxia-telangiectasia mutated (ATM) mediates the cellular response to DNA double strand breaks in human neuron-like cells. J Biol Chem 281: 17482–17491 | Article | PubMed | ChemPort |
  42. Robinson SH et al. (1987) Alzheimer's disease cells exhibit defective repair of alkylating agent-induced DNA damage. Ann Neurol 21: 250–258 | PubMed |
  43. Kodioglu E et al. (2004) Detection of oxidative DNA damage in lymphocytes of patients with Alzheimer's disease. Biomarkers 9: 203–209 | PubMed |
  44. Fishel ML et al. (2007) DNA repair in neurons: so if they don't divide what's to repair? Mutat Res 614: 24–36 | PubMed | ChemPort |
  45. Shackelford DA (2006) DNA end joining activity is reduced in Alzheimer's disease. Neurobiol Aging 27: 596–605 | Article | PubMed | ChemPort |
  46. Fukae J et al. (2005) Expression of 8-oxoguanine DNA glycosylase (OGG1) in Parkinson's disease and related neurodegenerative disorders. Acta Neuropathol (Berl) 109: 256–262 | PubMed | ChemPort |
  47. Martin JB (1999) Molecular basis of the neurodegenerative disorders. N Engl J Med 340: 1970–1980 | Article | PubMed | ISI | ChemPort |
  48. Sieradzan KA and Mann DM (2001) The selective vulnerability of nerve cells in Huntington's disease. Neuropathol Appl Neurobiol 27: 1–21 | Article | PubMed | ISI | ChemPort |
  49. Li JL et al. (2006) Genome-wide significance for a modifier of age at neurological onset in Huntington disease at 6q23-24: the HD MAPS study. BMC Med Genet 7: 71 | Article | PubMed | ChemPort |
  50. Sadri-Vakili G and Cha JH (2006) Mechanisms of disease: histone modifications in Huntington's disease. Nat Clin Pract Neurol 2: 330–338 | Article | PubMed | ChemPort |
  51. Hardy J and Orr H (2006) The genetics of neurodegenerative diseases. J Neurochem 97: 1690–1699 | Article | PubMed | ChemPort |
  52. Dere R and Wells RD (2006) DM2 CCTG*CAGG repeats are crossover hot spots that are more prone to expansions than the DM1 CTG*CAG repeats in Escherichia coli. J Mol Biol 360: 21–36 | Article | PubMed | ChemPort |
  53. El-Khamisy SF et al. (2005) Defective DNA single-strand break repair in spinocerebellar ataxia with axonal neuropathy-1. Nature 434: 108–113 | Article | PubMed | ISI | ChemPort |
  54. Brooks BP et al. (2005) Genotypic heterogeneity and clinical phenotype in triple A syndrome: a review of the NIH experience 2000–2005. Clin Genet 68: 215–221 | Article | PubMed | ChemPort |
  55. Hirano M et al. (2006) ALADINI482S causes selective failure of nuclear protein import and hypersensitivity to oxidative stress in triple A syndrome. Proc Natl Acad Sci USA 103: 2298–2303 | Article | PubMed | ChemPort |
  56. Rosen DR et al. (1993) Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis. Nature 362: 59–62 | Article | PubMed | ISI | ChemPort |
  57. Petri S et al. (2006) Cell-permeable peptide antioxidants as a novel therapeutic approach in a mouse model of amyotrophic lateral sclerosis. J Neurochem 98: 1141–1148 | Article |